Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Arcutis Biotherapeutics (ARQT) Gains from Investment Securities (2020 - 2025)

Arcutis Biotherapeutics has reported Gains from Investment Securities over the past 3 years, most recently at -$3.5 million for Q4 2025.

Quarterly results put Gains from Investment Securities at -$3.5 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$427000.0 (down 247.15% YoY), and the annual figure for FY2025 was -$652000.0, changed.
Gains from Investment Securities for Q4 2025 was -$3.5 million at Arcutis Biotherapeutics, down from $3.2 million in the prior quarter.
Over the last five years, Gains from Investment Securities for ARQT hit a ceiling of $3.2 million in Q3 2025 and a floor of -$3.5 million in Q4 2025.